<DOC>
	<DOCNO>NCT01546818</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , immune response killed-whole HIV-1 ( SAV001-H ) vaccine primary vaccination regimen HIV infect individual .</brief_summary>
	<brief_title>Safety Immune Response Assessment Study Killed-whole HIV-1 Vaccine ( SAV001-H ) Chronic HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 infect Chronic HIV infection define documentation HIV infection ne year . Prior antiretroviral therapy define minimum 6 month treatment HAART . ( HAART define combination least 2 antiretroviral agent . ) CD4+ cell count 350 cell per mm3 period 6 month prior study entry least 3 different time point ( one must obtain screen ) obtain laboratory posse CLIA certification equivalent . HIV1 RNA level less 50 copy per mL period 6 month prior study entry least 3 different time point ( one must obtain screen ) laboratory posse CLIA certification equivalent . Laboratory value obtain within 28 day prior study entry Men woman 18 50 year age Female study volunteer reproductive potential ( defined girl reach menarche woman postmenopausal least 24 consecutive month , i.e . menses within precede 24 month , undergone surgical sterilization ( e.g . hysterectomy , bilateral oophorectomy , salpingotomy ) must negative serum urine pregnancy test perform within 3 day initiate studyspecified medication . If participate sexual activity could lead pregnancy , female study volunteer must use form contraception list receive protocolspecified medication 6 month stop medication . At least one follow method MUST use appropriately ( without hormonebased method ) : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide IUD Informed , willing able comply , investigational nature study , sign informed consent form accordance institutional regulatory guideline History serious adverse reaction vaccine include anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain , except subject history adverse reaction pertussis vaccine child may enroll . History CD4+ count less 350 cell per mm3 , opportunistic infection , AIDSdefining illnesses . History autoimmune disease , immunodeficiency ( HIV infection ) , asthma , diabetes ( include Type II diabetes insulin resistance ) require insulin oral hypoglycemics , thyroid disease , bleed disorder , active malignancy , viral hepatitis , asplenia . HBVsAg , HCV Ab , RPR positive . Suspected allergy adverse reaction component study agent . Changes antiretroviral regimen within 6 month prior entry due virologic failure ( include toxicity ) . Pregnancy breastfeed . Receipt live attenuate vaccine investigational research agent within 30 day prior study entry . Receipt blood product within 120 day prior study entry . Receipt immunoglobulin within 60 day prior study entry . Receipt medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal , allergy treatment antigen injection ) within 14 day prior study entry . Receipt prior experimental HIV vaccine . Any investigational antiretroviral agent obtain expanded access . Receipt immunosuppressive medication within past 6 month ( e.g. , oral/parenteral/inhaled corticosteroid , and/or cytotoxic medication ) . NOTE : The follow allowed : corticosteroid nasal spray allergic rhinitis ; topical corticosteroid acute , uncomplicated dermatitis ; counter medication acute , uncomplicated dermatitis period longer 14 day . Current antiTB prophylaxis therapy . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Serious illness ( require systemic treatment and/or hospitalization ) subject either complete therapy clinically stable therapy , opinion investigator , least 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HIV-1 infection</keyword>
</DOC>